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Abstract 
 
It is now almost ten years that the United States of America, 
England, Italy and Japan have developed their own reporting 
system to classify thyroid lesions. Important confusion and 
uncertainties dominated the “follicular-patterned lesions”, a 
category also known as the “gray zone”. Every cytopathologist was 
using a personal terminology to describe and call lesions made up 
of a variable admixture of macro- and microfollicular structures. 
These personal views varied considerably between 
cytopathologists and generated a great deal of confusion among 
patients (the cytological report being almost incomprehensible to 
them), clinicians and even within the same cytopathology 
community. With the advent of national reporting systems, things 
changed in a better way and standardized reporting systems 
became the standard of practice in thyroid cytology. The outcome 
of the widespread use of standardized diagnostic categories was 
the reduction of descriptive diagnoses and the improved 
communication between cytopathologists, clinicians and patients. 
In this article we review the major reporting systems, analyze their 
similarities and differences in the “indeterminate” or “follicular-
patterned” diagnostic categories, and when possible, try to assess 
their performance. 
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Introduction 
 
Thyroid fine-needle aspiration (FNA) is one of the most 
commonly performed medical procedures all around the world. It 
is safe and easy to perform, and when coupled with ultrasound, 
allows even non-palpable and deep-seated nodules to be precisely 
located and sampled (1, 2). As thyroid ultrasound alone has low 
specificity and sensitivity to detect thyroid malignancies, FNA has 
become a natural complement for the initial investigation of 
thyroid nodules. Consequently, a spectacular increase of thyroid 
FNA has been observed. Cytopathologists have thus been facing a 
wider spectrum of lesions requiring not only a precise 
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morphological description but also a clear and concise diagnosis.  
Usually cytopathologists are aware of what is clearly benign and 
malignant, but they experience some limitations regarding the 
classification of lesions not belonging to these two extremities, the 
so-called “gray-zone” (3). 
Another problematic issue is the meaning of the 
“Indeterminate” diagnostic category (DC). In some reporting 
systems, it encompasses all follicular lesions or follicular-patterned 
lesions for which a benign diagnosis cannot be warranted; in other 
words those lesions are composed of a variable amount of 
microfollicular structures, the percentage of which is increasing 
with the risk of malignancy. According to other reporting systems 
used worldwide, this DC also includes lesions with nuclear atypia 
such as those suspicious but insufficient for a diagnosis of 
papillary thyroid carcinoma (PTC), lesions that present nuclear 
atypia in a context of fixation/staining artifacts, or lesions that 
show morphological findings inconsistent with the clinical 
presentation. 
If terminology defining follicular-patterned lesions is not 
clear, the same is true concerning the reporting of these lesions. In 
the past, a great majority of cytopathologists not even finished 
their reports with a final and clearly stated diagnosis, but used 
sibylline sentences reflecting their uncertainties. Some more 
audacious cytopathologists also signing out histopathological cases 
placed the follicular-patterned lesion in the benign category, 
knowing that a majority of these lesions turn out to be benign (or 
with a low degree of malignant potential) at histology. Other 
cytopathologists considered follicular-patterned lesions as 
malignant, leading to the impossibility to compare data from 
different institutions/hospitals. The unreliability of 
cytopathological reports and as a consequence the inability to 
identify malignancy in the follicular-patterned DC was responsible 
for the disuse of thyroid cytology. Fortunately, several cytological 
societies tried to set up a series of general recommendations. The 
first goal that had to be achieved was to keep thyroid cytology 
alive. New reporting systems were created and started to be used: 
the American, British, Italian and Japanese thyroid reporting 
systems. The standardization of the cytological report gained 
success immediately; it was not unusual to hear pathologists and 
clinicians refer to thyroid cytological results using acronyms 
related to DCs such as TIR3 for follicular lesion in the Italians 
reporting system (see below) instead of speaking of a lesion 
suspicious for a follicular neoplasm.  
Have the new classification systems lead to a consensus and a 
standardized terminology concerning the “Indeterminate” DC? Are 
the diagnostic performances comparable among the different 
reporting systems?   The aim of this study is to compare and assess  
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Table 1. Comparison between the four thyroid fine-needle aspiration reporting systems 
American, 2008 
(abbreviation) 
English, 2011 
(abbreviation) 
Italian, 2014 
(abbreviation) 
Japanese, 2013 
(abbreviation) 
Non-diagnostic or unsatisfactory  
cyst fluid only (I) 
Non-diagnostic for cytological 
diagnosis (Thy1) 
Unsatisfactory, consistent with 
cyst (Thy1c) 
Non diagnostic (TIR1) 
Non diagnostic - cystic (TIR1C) 
Inadequate (non-
diagnostic) (1) 
Benign (II) Non-neoplastic (Thy2/Thy2c) Non-malignant/benign (TIR2) Normal or benign (2) 
Atypia of undetermined 
significance or follicular lesion 
of undetermined significance. 
(AUS/FLUS) (III) 
Neoplasm possible - 
atypia/non-diagnostic (Thy3a) 
 
Low-risk indeterminate lesion 
(LRIL) (TIR3A) 
 
 
Indeterminate (3) 
   Follicular neoplasm (3A) 
   Others (3B) Follicular neoplasm or 
suspicious for a follicular 
neoplasm 
(FN/SFN) (IV) 
Neoplasm possible - suggesting 
follicular neoplasm (Thy3f) 
High-risk indeterminate lesion 
(HRIL) (TIR3B) 
 
Suspicious of malignancy (V) 
Suspicious of malignancy 
(Thy4) 
Suspicious of malignancy (TIR4) Malignancy suspected (4) 
Malignant (VI) Malignant (Thy5) Malignant (TIR5) Malignancy (5) 
 
the performance of the American, British, Italian and Japanese 
systems for reporting thyroid cytopathology regarding the 
indeterminate follicular-patterned DC. 
 
The American (Bethesda) reporting system 
 
The American reporting system, known under the acronym 
TBSRTC (The Bethesda System for Reporting Thyroid Cytology), 
is probably the most diffusely used. It is born from the initiative of 
the National Cancer Institute in 2007 in Bethesda (MD, United 
States). The Conference was preceded by long and profitable web-
based discussions guided by steering committees in charge of 
orientating the discussion to the proper segment. Andrea Abate 
organized the conference and Syed Z. Ali and Edmund S. Cibas 
were the editors driving the publication of the Bethesda Atlas (4). 
A web-based atlas of images is also available. This system, that 
has not been revised yet, is a 6-tiered system consisting of the 
following six DCs: 1) non-diagnostic/unsatisfactory (ND/U); 2) 
benign (B); 3) atypia of undetermined significance or follicular 
lesion of undetermined significance (AUS/FLUS); 4) follicular 
neoplasm/suspicious for a follicular neoplasm (FN/SFN); 5) 
suspicious for malignancy (SM); and 6) malignant (M). The most 
important and innovative feature of this system, probably 
explaining its immediate success, is the association of the DCs 
with a malignancy risk and a proposed action. This scheme helps 
to standardize not only the reporting terminology, but also to 
clarify treatment options (Table 1). 
 
The English (RCPath) reporting system 
 
The English system was started in 2002 by the British 
Thyroid Association (BTA)-Royal College of Pathologists 
(RCPath). By 2007, the terminology comprising five DCs became 
rapidly widespread in UK. In 2009, the RCPath published a 
modified system under the name of “Guidance on the reporting 
cytology specimens” that was put on the RCPath for comment 
before its definitive release (5). It comprised the following DCs: 
non-diagnostic (also reported as Thy1), under which was created a 
new subcategory, namely the Thy1c (“c” for cystic lesion with 
macrophages and no colloid); non-neoplastic (Thy2), with a 
subcategorization (Thy2c) for cystic lesions containing 
macrophages and colloid and can be considered non-neoplastic in 
the appropriate clinical setting; neoplasm possible (Thy3), that 
encompasses the most common Thy3f (“f” for follicular lesion) 
and Thy3a (“a” for atypia) for cases containing architectural and/or 
nuclear atypia insufficient to be placed in a higher category or 
cases compromised by preparation/staining artifacts; suspicious of 
malignancy (Thy4); and malignant (Thy5). More recently, the 
BTA released the third edition of their guidelines for the 
management of thyroid cancer (6). In the preface to the section 
dedicated to FNA cytology, following the 2009 RCPAth 
“Guidance on the reporting cytology specimens”, are enumerated 
some points of good practice (5). It is stated, for example, that the 
numerical category (Thy1-5) should also be written along with a 
descriptive paragraph containing the interpretative findings. It is 
also stated that the UK DCs map exactly TBSRTC DCs (Table 1). 
  
The Italian (SIAPEC/IAP) reporting system  
 
The Italian system was originally issued in 2007 by the Italian 
Society for Anatomic Pathology and Cytopathology (SIAPEC)-
International Academy of Pathology (IAP) in association with the 
Italian Society of Endocrinology and the Endocrinologist Medical 
Association (7). This was a 5-tiered system consisting of the 
following DCs: 1) non-diagnostic, also reported as (TIR1), 2) 
negative for malignant cells (TIR2), 3) inconclusive/indeterminate 
(follicular proliferation) (TIR3), 4) suspicious for malignancy 
(TIR4), and 5) diagnostic of malignancy (TIR5). It has been 
recently revised by the SIAPEC in agreement with the Italian 
Society of Endocrinology, the Endocrinologist Medical 
Association and the Italian Association of Thyroid (see the article 
by Fadda G et al. in the present issue for more explication). 
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Briefly, the two most important additional features present in the 
revised version are 1) the association of a malignancy risk to each 
DC, in analogy with TBSRTC and 2) new subcategories in the 
TIR1 and TIR3 DCs. In particular, a new subcategory of TIR1, 
called TIR1 cystic (C), covers aspirates only containing cyst fluid, 
a material in itself non-diagnostic that can however be considered 
benign if US and clinical features point toward a benign lesion. 
The TIR3 DC was splitted into low and high risk of malignancy 
(Table 1). 
 
The Japanese reporting system 
 
 The Japanese thyroid reporting system was issued in 2005, as 
published by the Japanese Society of Thyroid Surgery based on the 
recommendations of the Papanicolaou society (8). This was a 5-
tiered system consisting of the following DCs: 1) inadequate (non-
diagnostic), 2) normal or benign, 3) indeterminate, 4) malignancy 
suspected (not conclusive for malignancy), and 5) malignancy. In 
2013, the Japan Thyroid Association proposed a new version of the 
reporting system, the more evident modifications being the 
subcategorization of the Indeterminate DC (9, 10). This DC has 
been divided into A: Follicular neoplasms; and B: Others. Cases 
with papillary carcinoma-type nuclei are excluded from category 
A. The “follicular neoplasms” are cases with architectural atypia in 
the sense of microfollicular structures and are further subdivided 
into A-1: favor benign; A-2: borderline; and A-3: favor malignant; 
depending on cellular atypia, loss of cellular cohesiveness, loss of 
cell polarity and architectural features (trabecular, tubular, 
microfollicular growth patterns). The use of these three 
subcategories remains optional in cytological reports. In the group 
“Indeterminate A” are also included cases of the PTC, follicular 
variant. The “Others” are lesions that are not follicular, but that 
harbor features of undetermined significance, in most cases 
represented by equivocal nuclear features of PTC.  
 
Indeterminate and atypical category 
 
For 5-tiered reporting systems, the “gray zone” is represented 
by the Thy3 DC (UK classification), the TIR3 DC (Italian 
classification), and the Indeterminate DC (Japanese classification). 
The American classification comprises formally another DC for 
“atypical cases”: the AUS/FLUS that together with the FN/SFN 
and the Suspicious for Malignancy DC are often considered 
together into the “Indeterminate” category. If we want to compare 
similar DC, we have to split the Indeterminate DC into subgroups. 
According to different papers, it is clearly stated that the UK 
Thy3a DC is equivalent to the AUS/FLUS DC (11, 12). For the 
Italian classification, the TIR3A could also be considered 
equivalent to the AUS/FLUS DC, and the management of both DC 
is repeat FNA (13). For the Japanese classification, Indeterminate 
B DC is the one that matches best the AUS/FLUS concerning the 
atypical nuclei scenarios, as in the Japanese classification this 
category does not include cases with poor 
preservation/fixation/staining (9). Considering incidence and risk 
of malignancy in the American, UK, Italian and Japanese 
classifications, these are reported to be <7% and 5-15%, 4.6% and 
9.5-43%, <10% and <10%, and 3.2% and 40-60%, respectively. 
The lower malignancy risk observed in the Italian classification is 
probably related to the atypical nuclear features being placed in the 
TIR3B category. In the AUS/FLUS DC of the Bethesda system, if 
we only consider the nuclear atypia scenario, then the malignancy 
risk is much higher than reported, varying from 38% to 56% (14-
16).  
Follicular neoplasm 
 
When speaking of FN, we refer histologically to nodular 
hyperplasia, follicular adenoma and follicular carcinoma, i.e. 
lesions that require surgical excision for accurate diagnosis. 
Meticulous microscopic examination of the capsule surrounding 
follicular proliferations looking for vascular and/or capsular 
invasion is mandatory for a diagnosis of malignancy. The 
cytological alter ego of what is described above is the “follicular-
patterned lesion”.  No definitive cytological diagnosis can be made 
and usually the material is composed of a variable admixture of 
mainly microfollicular structures. For these lesions, thyroid FNA is 
considered a screening test, orientating patients toward surgery. 
Several synonyms are used to indicate this category: follicular 
neoplasm/suspicious for a follicular neoplasm/neoplasm possible 
(suggesting follicular neoplasm). It is referred to FN in this article.  
Correspondence in the different classification systems can be 
established as follows: FN/SFN in the American system, Thy3f in 
the UK system, TIR3B in the Italian system and Indeterminate A-3 
in the Japanese system. Some classification schemes, as the 
Japanese one, tried to further stratify FN according to cellular 
atypia, loss of cell polarity, loss of cellular cohesiveness, and 
structural abnormality in order to further prevent unnecessary 
surgeries (9).  
Is it possible to compare the diagnostic accuracy of the FN 
DC? In a paper published in 2012, no significant differences were 
demonstrated in the positive predictive value (PPV) for the FN DC 
between the American and the Italian reporting systems (26.5% vs. 
32.1%, P = 0.2531) (17). Differences were noted in the rate of 
cases diagnosed as FN (4.6% vs. 23.8%, P < 0.0001) and in the 
percentage of patients that underwent surgery (56.4% vs. 78.8%, P 
< 0.0001), probably indicating that medico-legal issues affected 
more USA-based clinicians than European-based ones. Data from 
the Japanese classification are not really comparable to the other 
reporting systems, as patients with FN are further stratified into 
Favor benign, Borderline and Favor malignant subcategories. Most 
importantly, the reported malignancy risk for the American FN DC 
of 15-30% that per se requires surgical treatment in the United 
States is not considered in Japan so high to require surgical 
treatment, at least not-without any other adjunct evaluation. 
Despite these limitations, cases placed in the FN DC are 4.3% in a 
recent analysis (Sugino et al. in the present issue), being more 
similar to the above reported study in the Italian classification 
(4.6%) and far away for the data reported by a meta-analysis of 
10.1% in the American classification (18). Medico-legal issues are 
probably less an obstacle to report thyroid cytology in Japan. 
However, data from the article by Sugino et al. from the Ito 
Hospital, Tokyo, Japan, presented a PPV value of 35.7% in the FN 
DC as a whole. If we look at the Indeterminate DC A-3 (Favor 
malignant), the PPV value is extremely high (50%)  (9).  
 In a study about the UK classification, FN DC (Thy3f) 
represented 13.6% of total cases (12). No data are available so far 
concerning the frequency and the malignancy risk in the new 
TIR3B DC, but the authors of the revised Italian classification 
hope that its frequency will be lower than 10% and that its cancer 
risk will be comprised between 20% and 30% (13).  
In consideration to the treatment of FN lesions, something 
similar to the Japanese proceeding is also present in the UK 
classification scheme, where a surgical action is not formally 
required for patients with a Thy3f lesion: these situations are better 
discussed in multidisciplinary meetings.  
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Different approaches 
 
Probably the most striking difference between all these 
classification systems is the discussion (British, Italian and 
Japanese systems) or not (American system) of FN cases in 
multidisciplinary meetings before deciding if surgery is indicated 
and the threshold of malignancy risk adequate for surgery between 
Western countries and Japan, Japan being more conservative in 
this aspect.  
 
Conclusions 
 
In our opinion, we are far from using a common and 
worldwide diffuse reporting system concerning FN of the thyroid. 
Each reporting system uses different acronyms, terminology and to 
a certain extent definitions (FN/SFN, Thy3, TIR3, Indeterminate) 
and this fact does not facilitate standardization of reporting 
systems and communication between people. Moreover, European 
countries have a different approach for the management of FN in 
comparison to United States and Western countries have a more 
aggressive approach concerning FN in comparison to Japan.  
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